Rewalk Robotics Ltd. ( (LFWD) ) has released its Q2 earnings. Here is a breakdown of the information Rewalk Robotics Ltd. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lifeward Ltd., a global leader in innovative medical technology, specializes in developing solutions for individuals with physical limitations, offering products like the ReWalk Exoskeleton and AlterG Anti-Gravity system. In its second quarter of 2025 financial results, Lifeward reported significant achievements, including a record number of ReWalk systems placed for Medicare beneficiaries and the appointment of new CEO and CFO to drive strategic change. The company achieved FDA clearance for the ReWalk 7 and expanded its U.S. payer base, reflecting positive market reception and strategic partnerships. Financially, Lifeward’s revenue decreased by 15% compared to the previous year, primarily due to the absence of one-time Medicare-related revenue, although operational efficiencies led to improved cash burn and gross margins. Despite a net loss of $6.6 million, Lifeward’s management remains optimistic, focusing on operational efficiencies and strategic growth initiatives to achieve its financial guidance for 2025.